^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    1d
    TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=675, Recruiting, AstraZeneca | Trial completion date: May 2030 --> Dec 2029 | Trial primary completion date: Apr 2028 --> Dec 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    1d
    AK117-203: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Jul 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)
    1d
    AK104-223: A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. (clinicaltrials.gov)
    P2, N=100, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tinengotinib (TT-00420) • Kaitanni (cadonilimab) • Yidafan (ivonescimab)
    1d
    A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence (clinicaltrials.gov)
    P3, N=198, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P3 trial
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    1d
    Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Guangdong Provincial People's Hospital
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)
    1d
    A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Georgetown University | Trial completion date: Nov 2027 --> Nov 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Loqtorzi (toripalimab-tpzi)
    1d
    SYS6090 Combination Therapy in Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=596, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P1/2 trial
    |
    Avastin (bevacizumab) • paclitaxel • docetaxel • pemetrexed • etoposide IV • SYS6010
    1d
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Recruiting, Merck Sharp & Dohme LLC | N=57 --> 190
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    1d
    SNAPI: Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer (clinicaltrials.gov)
    P2, N=15, Terminated, M.D. Anderson Cancer Center | N=88 --> 15 | Trial completion date: Jan 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Mar 2026; <75% participation
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516)
    1d
    ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 (clinicaltrials.gov)
    P1/2, N=31, Not yet recruiting, University of Wisconsin, Madison
    New P1/2 trial
    |
    Inqovi (decitabine/cedazuridine) • Zynyz (retifanlimab-dlwr)
    1d
    A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (clinicaltrials.gov)
    P3, N=675, Recruiting, Merck Sharp & Dohme LLC | N=218 --> 675
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)
    1d
    SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (clinicaltrials.gov)
    P=N/A, N=49, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    Tyvyt (sintilimab) • capecitabine • Onivyde (nanoliposomal irinotecan)